Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
April 27 2021 - 4:01PM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel T cell-based cancer
immunotherapies, will report its first quarter financial results on
Thursday, May 6, 2021. Management will host a conference call and
live audio webcast to discuss these results and provide a corporate
update at 4:30 p.m. ET.
To participate in the conference call, please dial
1-800-773-2954 (domestic) or 1-847-413-3731 (international) and
reference the access code 50155289. The live webcast can be
accessed in the Investors section of the Company’s website at
www.iovance.com. The archived webcast will also be available for
one year in the Investors section at www.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to improve patient care by
making T cell-based immunotherapies broadly accessible for the
treatment of patients with solid tumors and blood cancers. Tumor
infiltrating lymphocyte (TIL) therapy uses a patient’s own immune
cells to attack cancer. TIL cells are extracted from a patient’s
own tumor tissue, expanded through a proprietary process, and
infused back into the patient. Upon infusion, TIL reach tumor
tissue, where they attack cancer cells. The company has completed
dosing in pivotal programs in patients with metastatic melanoma and
cervical cancer. In addition, the company’s TIL therapy is being
investigated in a registration-supporting study for the treatment
of patients with locally advanced, recurrent or metastatic
non-small cell lung cancer. Clinical studies are also underway to
evaluate TIL in earlier stage cancers in combination with currently
approved treatments, and to investigate Iovance peripheral blood
lymphocyte (PBL) T cell therapy for blood cancers. For more
information, please visit www.iovance.com.
CONTACTS
Iovance Biotherapeutics, Inc:Sara Pellegrino,
IRCVice President, Investor Relations & Public
Relations650-260-7120 ext. 264Sara.Pellegrino@iovance.com
Solebury Trout:Zara
Lockshin (media)646.378.2960zlockshin@soleburytrout.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024